MDM2 and Thrombocytopenia: Extensive PK/PD modelling is used in [122] to improve the dosing of yet another inhibitor of p53-Mdm2 interaction, CGM097, in order to predict patients with higher risk to develop thrombocytopenia; haematologic toxicity with delayed thrombocytopenia is a well-known side effect of Mdm2 inhibitors.